不同OCT分型的视网膜静脉阻塞性黄斑水肿与血清中血管内皮生长因子水平的相关性

doi:10.3969/j.issn.1671-7171.2026.03.026

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1254 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the correlation between different optical coherence tomography (OCT) classifications of retinal vein occlusion macular edema (RVO-ME) and serum vascular endothelial growth factor (VEGF) levels. 【Methods】 Clinical data of 138 patients (138 eyes) with RVO-ME diagnosed and treated in the ophthalmology department of our hospital from December 2022 to December 2024 were retrospectively analyzed. According to the site of retinal vein occlusion, patients were divided into central retinal vein occlusion group and branch retinal vein occlusion group. According to OCT features, RVO-ME patients were classified into diffuse retinal thickening type group (n=25), serous retinal detachment type group (n=58), and cystoid macular edema type group (n=55). Meanwhile, 50 patients (50 eyes) undergoing cataract surgery who were diagnosed and treated in our ophthalmology department and excluded from fundus diseases were selected as the control group. Serum VEGF levels were measured and compared among all groups. 【Results】 Serum VEGF levels in both central retinal vein occlusion group and branch retinal vein occlusion group were significantly higher than those in the control group (P<0.05). There were statistically significant differences in the distribution of central retinal vein occlusion and branch retinal vein occlusion among diffuse retinal thickening type, serous retinal detachment type and cystoid macular edema type RVO-ME patients (P<0.05). Statistically significant differences were found in serum VEGF levels among RVO-ME patients with different OCT classifications (P<0.05). 【Conclusion】 Serum VEGF levels differ in RVO-ME patients with different OCT classifications, and are closely related to the site of retinal vein occlusion and the type of macular edema, suggesting that VEGF may play an important role in the pathogenesis and progression of RVO-ME.

Key words： Macular Edema Retinal Vein Occlusion Vascular Endothelial Growth Factor A Correlation of Data

Received: 19 February 2025

PACS:

R774.5

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HU Xumeng
	WANG Feiyan

Cite this article:

HU Xumeng,WANG Feiyan. Correlation between Different OCT Classifications of Retinal Vein Occlusion Macular Edema and Serum Vascular Endothelial Growth Factor Levels[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(3): 446-448.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.03.026 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I3/446

[1] DAVID G,BOBBY T,CAROLINE B,et al.Real-world outcomes of intravitreal bevacizumab treat-and-extend for cystoid macular oedema secondary to central retinal vein occlusion[J].Int Ophthalmol,2023,43(11):4105-4110.
[2] LIANG J,XIONG T,CHEN H Q,et al.Effects of Ranibizumab combined with laser photocoagulation on macular volume and best corrected visual acuity in patients with macular edema secondary to ischemic retinal vein occlusion[J].Pak J Med Sci,2023,39(2):385-389.
[3] 王娟,李东,胡倩,等. 老年视网膜静脉阻塞性黄斑水肿患者抗VEGF治疗预后的相关因素[J].中国老年学杂志,2023,43(12):2940-2942.
[4] KANG J W,CHUNG H,CHAN KIM H. Correlation of optical coherence tomographic hyperreflective foci with visual outcomes in different patterns of diabetic macular edema[J].Retina,2016,36(9): 1630-1639.
[5] SCHMIDT-ERFURTH U,GARCIA-ARUMI J,GERENDAS B S,et al. Guidelines for the management of retinal vein occlusion by the European society of Retina specialists ( EURETINA)[J]. Ophthalmologica,2019, 242 (3) : 123-126.
[6] 蒋菲菲,周利晓,齐若,等. 不同OCT分型的视网膜静脉阻塞性黄斑水肿与血小板参数的关系[J].国际眼科杂志,2021,21(10):1816-1819.
[7] 郝壮,王珏,冀帅飞,等. 抗VEGF药物联合皮质类固醇激素治疗视网膜静脉阻塞性黄斑水肿的Meta分析[J].国际眼科杂志,2021,21(1):99-105.
[8] 李静,谷威. 地塞米松玻璃体腔植入剂对难治性视网膜静脉阻塞继发黄斑水肿的疗效[J].中华实验眼科杂志,2021,39(5):444-449.
[9] 郭超,周庆芸,李琦. 地塞米松玻璃体植入剂治疗视网膜静脉阻塞性黄斑水肿的研究概况[J].中国药房,2019,30(15):2155-2160.
[10] 蒋萌,张明. 抗VEGF药物玻璃体内注射诱发感染性眼内炎的研究现状[J].眼科新进展,2023,43(7):580-584.
[11] 付燕,杨娜,李丽英,等. 抗血管内皮生长因子药物治疗对视网膜静脉阻塞合并黄斑水肿患眼脉络膜厚度的影响[J].中华眼底病杂志,2021,37(9):681-686.
[12] 丁雪菲,李秋明,赵秋朴,等. 抗VEGF或抗炎治疗对视网膜静脉阻塞继发不同类型黄斑水肿的短期疗效比较[J].国际眼科杂志,2022,22(3):500-504.
[13] 范琳华,滕思莹,惠鹏,等. 抗血管内皮生长因子在视网膜静脉阻塞继发黄斑水肿的临床研究[J].中国实验诊断学,2021,25(3):406-409.
[14] 刘明月,陈佳玉,常晨,等. 炎症及动脉硬化相关因子与视网膜静脉阻塞的相关性[J].国际眼科杂志,2020,20(7):1264-1268.
[15] 浦利军,承伟,顾晖晖,等. 不同激光光凝治疗时机联合玻璃体注射康柏西普治疗视网膜中央静脉阻塞继发黄斑水肿的有效性及安全性[J].中国老年学杂志,2020,40(10):2124-2127.
[16] 邱煦,窦宏亮,陈凤华,等. 玻璃体腔注射抗血管内皮生长因子药物对视网膜微循环的影响研究现状与进展[J].中华眼底病杂志,2020,36(7):565-570.